search
Back to results

"Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies (IMPACTURO)

Primary Purpose

Urological Manifestations

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
ORAL IMPACT treatment
control
Sponsored by
Raincy Montfermeil Hospital Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urological Manifestations focused on measuring cystectomy,, nephrectomy,, laparotomies, reduction of postoperative complications

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age and older
  • Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
  • Having expressed their free and informed consent.
  • Affiliated to a social security scheme

Exclusion Criteria:

  • Immune deficiency.

    • HIV infection.
    • Curative surgery for chronic urinary tract infection.
    • Urgent surgery.
    • Inability to take oral impact 7 days before surgery.
    • Unstable psychiatric state.
    • Infection with COVID 19 during postoperative stay.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    ORAL impact group

    control

    Arm Description

    This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.

    a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact

    Outcomes

    Primary Outcome Measures

    Rate of major postoperative complications
    the number of postoperative complications during this study for each patient

    Secondary Outcome Measures

    Length of stay in hospital (LOS).
    Length of stay in hospital (LOS). durind the participation of each patient
    Number of admissions in intensive care setting for severe complications.
    Number of admissions in intensive care setting for severe complications after major urological surgery.
    Rate of transfusions of red blood cells.
    Rate of transfusions of red blood cellsduring hospitalisation and after major urological surgery.
    mortality rate
    3-month mortality rate

    Full Information

    First Posted
    August 25, 2022
    Last Updated
    August 25, 2022
    Sponsor
    Raincy Montfermeil Hospital Group
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05520151
    Brief Title
    "Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies
    Acronym
    IMPACTURO
    Official Title
    "Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2022 (Anticipated)
    Primary Completion Date
    January 2025 (Anticipated)
    Study Completion Date
    June 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Raincy Montfermeil Hospital Group

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynaecological and cardiac surgery . Studies in major Urological surgery are rare and are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
    Detailed Description
    Major surgery induces a traumatic stress due to the surgical aggression that could lead to major postoperative complications and death when the patient organism is not ready or prepared to support this intense corporeal stress. Malnutrition can be caused by chronic starvation, chronic inflammatory disease and acute injury (stress, acute inflammation). Therefore, nutritional supplements are indicated for patients who do not meet their energy needs through oral food ingestion. Immune-modulating nutrient-enriched products containing arginine, Omega-3 polyunsaturated fatty acids (PUFAs), nucleic acids, vitamins and antioxidants (selenium) like ORAL IMPACT (Nestlé) can modulate immune and inflammatory processes in burn, trauma, major surgery and improve clinical outcomes. These immune-modulating nutrient-enriched products have shown their ability to decrease postoperative complications up to 50% in patients undergoing non-gastrointestinal major surgery and length of hospital and ICU stay (Jie B 2012, Drover 2011). Mortality benefit has been demonstrated in one study focused on Neck and Head surgery. (Buijs N, 2010) Before 2019, in our urology surgery setting, it seemed that the postoperative complications rate was clinically increasing despite reliable surgeons and excellent surgery techniques and procedures. It appeared that the sources of these complications might be the weakness of the patients against major surgical stress. Patients might have been malnourished. The nutrition status had been omitted from our preoperative anesthesia assessment and none perioperative nutritional rehabilitation had been performed. The effect of immune-modulating nutrient-enriched products had been demonstrated mostly in gastrointestinal surgery but also in non-gastrointestinal surgeries such as neck and head cancer surgery, gynecologic cancer surgery and cardiac surgery. There are not studies conducted in urologic major surgery. Reducing the number of post-operative complications is a major challenge in surgery because they cause an increase in the length of stay, which translates into higher hospital costs for the community. Surgery is an act that generates major metabolic stress that the human body must contain. This metabolic stress will manifest itself in an increase in catabolism and a decrease in anabolism, resulting in protein-energy malnutrition in the patient if this latter is insufficiently prepared. Preoperative undernutrition is one of the risk factors for major postoperative complications. Numerous studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal surgery, ear-nose and throat, gynecological and cardiac surgery. No studies have been done in major Urological surgery The proposed study will be the first formal evaluation of the benefits and risks of using ORAL IMPACT in preoperative period of urology surgery. The choice of this clinical project for this research question is justified by the proven benefit of this food substitute perioperatively in gastrointestinal, ear-nose and throat, gynecological and cardiac surgery. We hypothesize that Oral Impact will protect against major postoperative complications and prolonged hospital stay for included patients undergoing urological surgery. There are no current guidelines recommending or discouraging the prescription of ORAL IMPACT in urological surgery patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urological Manifestations
    Keywords
    cystectomy,, nephrectomy,, laparotomies, reduction of postoperative complications

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Model Description
    Prospective non-randomized clinical study comparing the group of patients who received a 7-days course of ORAL IMAPCT to a retrospective cohort of patients operated between 2016 and 2019: cystectomy and nephrectomy by laparotomy.
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    214 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    ORAL impact group
    Arm Type
    Experimental
    Arm Description
    This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.
    Arm Title
    control
    Arm Type
    Other
    Arm Description
    a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    ORAL IMPACT treatment
    Intervention Description
    the group of patients will be received a 7-days course of ORAL IMPACT
    Intervention Type
    Other
    Intervention Name(s)
    control
    Intervention Description
    no intervention
    Primary Outcome Measure Information:
    Title
    Rate of major postoperative complications
    Description
    the number of postoperative complications during this study for each patient
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    Length of stay in hospital (LOS).
    Description
    Length of stay in hospital (LOS). durind the participation of each patient
    Time Frame
    3 months
    Title
    Number of admissions in intensive care setting for severe complications.
    Description
    Number of admissions in intensive care setting for severe complications after major urological surgery.
    Time Frame
    3 months
    Title
    Rate of transfusions of red blood cells.
    Description
    Rate of transfusions of red blood cellsduring hospitalisation and after major urological surgery.
    Time Frame
    3 months
    Title
    mortality rate
    Description
    3-month mortality rate
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 18 years of age and older Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies. Having expressed their free and informed consent. Affiliated to a social security scheme Exclusion Criteria: Immune deficiency. HIV infection. Curative surgery for chronic urinary tract infection. Urgent surgery. Inability to take oral impact 7 days before surgery. Unstable psychiatric state. Infection with COVID 19 during postoperative stay.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Serge Ndoko, MD
    Phone
    01.49.36.70.41
    Ext
    +33
    Email
    serge.ndoko@ght-gpne.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Sabrina Lassouani, MD
    Phone
    01.49.36.70.41
    Ext
    +33
    Email
    sabrina.lassouani-amara@ght-gpne.fr

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    24009246
    Citation
    Finnerty CC, Mabvuure NT, Ali A, Kozar RA, Herndon DN. The surgically induced stress response. JPEN J Parenter Enteral Nutr. 2013 Sep;37(5 Suppl):21S-9S. doi: 10.1177/0148607113496117.
    Results Reference
    result
    PubMed Identifier
    18419494
    Citation
    Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008 May 15;46(10):1582-8. doi: 10.1086/587658.
    Results Reference
    result
    PubMed Identifier
    16437757
    Citation
    Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9 Suppl 2:S39-50. doi: 10.1016/j.ejon.2005.09.006.
    Results Reference
    result
    PubMed Identifier
    21556200
    Citation
    Barker LA, Gout BS, Crowe TC. Hospital malnutrition: prevalence, identification and impact on patients and the healthcare system. Int J Environ Res Public Health. 2011 Feb;8(2):514-27. doi: 10.3390/ijerph8020514. Epub 2011 Feb 16.
    Results Reference
    result

    Learn more about this trial

    "Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies

    We'll reach out to this number within 24 hrs